PCSK9 and metabolic dysfunction-associated steatohepatitis: Whether the pharmacological inhibition of PCSK9 either by monoclonal antibodies or siRNAs has similar effects in morbidly obese patients with NAFLD or NASH has not been studied yet, nor has the sex-specific hepatic response of patients to PCSK9 inhibitors.